Ekso Bionics Files Proxy Materials

TL;DR

EKSO filed proxy docs, no fee. Standard procedure.

AI Summary

Ekso Bionics Holdings, Inc. filed a Definitive Additional Materials proxy statement on June 3, 2024. This filing is related to the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The company is incorporated in Nevada and its fiscal year ends on December 31.

Why It Matters

This filing indicates that Ekso Bionics is proceeding with its corporate governance and shareholder communication processes, which are essential for the ongoing operations and strategic decisions of the company.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement, indicating standard corporate governance procedures rather than a specific event with immediate financial risk.

Key Players & Entities

• EKSO BIONICS HOLDINGS, INC. (company) — Registrant
• 0001437749-24-019063 (filing_id) — Accession Number
• 20240603 (date) — Filing Date

FAQ

Filing Documents

• ekso20240603_defa14a.htm (DEFA14A) — 13KB
• 0001437749-24-019063.txt ( ) — 14KB

From the Filing

ekso20240603_defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Under 240.14a-12 Ekso Bionics Holdings, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 SUPPLEMENT TO DEFINITIVE PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 6, 2024 On April 26, 2024, Ekso Bionics Holdings, Inc. (the "Company") filed with the Securities and Exchange Commission a definitive proxy statement on Schedule 14A (the "Proxy Statement") relating to the Company's 2024 Annual Meeting of Stockholders to be held on June 6, 2024 at 9:00 a.m. PDT (the "Annual Meeting"). The Company is providing this proxy statement supplement (this "Supplement") solely to correct the year reference in certain descriptions of the proposal relating to election of the persons to serve on the Company's Board of Directors in the Proxy Statement and in the accompanying Notice of Annual Meeting (the "Notice"), which incorrectly stated that, if elected, such persons would serve until the Company's annual meeting of stockholders to be held in "2024" rather than "2025." To reflect such change, the Company hereby replaces in its entirety the language describing Proposal One in the Notice and on page 1 of the Proxy Statement with the following: 1. To elect five persons to our Board of Directors, to serve until the annual meeting of stockholders to be held in 2025 and until their respective successors are elected and qualified, or until their earlier death, resignation or removal; This Supplement should be read in conjunction with the Proxy Statement and Notice. Except as specifically set forth in this Supplement, no other changes are made to the Proxy Statement or the Notice. If you have already submitted your vote, you do not need to take any action.

View Full Filing

View this DEFA14A filing on SEC EDGAR